Launch of the First Pre-Clinical Phase of the FAST-Tx Project at IHU Strasbourg

Launch of the First Pre-Clinical Phase of the FAST-Tx Project at IHU Strasbourg

An ambitious project to transform the patient care pathway

The FAST-Tx project (Fast Analysis and Surgical Treatment – Thorax), winner of the 2025 FORCE Foundation Award for Innovation and Health Research, has reached a decisive milestone with the operational start of its first pre-clinical study phase at IHU Strasbourg.

Led by Prof. Pierre-Emmanuel FALCOZ and Dr. Cezar Matau, this project aims to reduce the time between diagnosis and treatment of suspicious pulmonary nodules to a single day — a major step forward for patients and a true paradigm shift in care organization.

In vivo testing to validate technological innovations

After several months of preparation, the teams from IHU Strasbourg and the University Hospitals of Strasbourg have launched the active phase of operational experiments, marked by the arrival of Intuitive’s ION robotic platform at the IHU.
The project also integrates Visible Patient Lab’s digital models and Asaria’s EagleEye augmented reality system, which leverages imaging data from the ION robot, CBCT (Cone Beam Computed Tomography), and the bronchoscope.

© Bernard Dubois, Founder and President of ASARIA.

Technological convergence serving the patient

FAST-Tx embodies the convergence of robotic surgery, augmented reality, digital twin technology, and artificial intelligence to accelerate diagnosis and treatment while improving the patient experience.
This innovative approach is made possible by IHU Strasbourg’s cutting-edge infrastructure and demonstrates how translational research can generate tangible, directly beneficial solutions for clinical care.

© Bernard Dubois, Founder and President of ASARIA.

A synergy between research, clinic, and industry

This ambitious project would not have been possible without the commitment of numerous partners:

FAST-Tx is built on close collaboration between researchers, clinicians, and industry partners, showcasing the potential of medical innovation when clinical expertise and technological progress come together.

Towards faster, more precise, and more human medicine

With the operational launch of this pre-clinical phase, FAST-Tx marks a strategic milestone in the multidisciplinary outreach of IHU Strasbourg and its partners, who are proud to contribute to this major advancement in the fight against lung cancer.

Listen to the interview (French) with Professor Jean Sibilia on ici Alsace 
As part of the launch of the pre-clinical phase of the FAST-Tx project, Professor Jean Sibilia, President of the FORCE Foundation for Innovation and Research in Health and Dean of the Faculty of Medicine in Strasbourg, was a guest on Ici Alsace radio on Tuesday, October 21.

During the interview, he discussed the challenges of the FAST-Tx project and the mission of the Strasbourg IHU: to accelerate the transfer of innovation to patients and strengthen synergies between research, clinical practice, and industry.

Listen to the full interview here

Scialytics : IHU spin-off is building the first AI powered end-to end ecosystem to measure and reduce surgical risk

Scialytics : IHU spin-off is building the first AI powered end-to end ecosystem to measure and reduce surgical risk

Every year, millions of patients worldwide face preventable surgical complications, ranging from bleeding to infections, that extend recovery times, increase healthcare costs, and put lives at risk. Despite advances in surgical techniques, hospitals still lack tools to measure and reduce risk during operations.

Scialytics, a spin-off of the IHU Strasbourg, is tackling this challenge head-on, drawing on more than a decade of cutting-edge research in surgical AI within the CAMMA research group, a joint IHU – University of Strasbourg lab led by Prof. Nicolas Padoy, one of the world’s leading figures in surgical data science and CSO of IHU Strasbourg.

Having benefited from Bpifrance French Tech LAB financing and incubation through the regional Quest for Health start-up incubator, the company has developed the world’s first AI-powered end-to-end ecosystem designed to analyze surgical video in real time, supporting surgeons during critical steps and enabling data-driven quality assurance across healthcare systems.

With backgrounds shaped in the IHU Strasbourg’s unique multidisciplinary and highly connected environment, the founding team brings together complementary expertise in data science, engineering, and surgery to translate over a decade of research into practical innovation that raises clinical standards:

  • Deepak Alapatt, MSc – CEO
  • Dr Pietro Mascagni, MD, PhD – Chief Medical Officer
  • Dr Luca Sestini, PhD – Chief Technology Officer
  • Dr Tong Yu, PhD – Head of Product
  • Prof. Nicolas Padoy – Scientific Advisor

2025 Milestones: From Lab to OR

Scialytics has already achieved key regulatory and clinical milestones:

  • FDA feedback confirmed a streamlined approval pathway for its first software-as-a-medical-device product: a real-time assistant for laparoscopic cholecystectomy (gallbladder removal).
  • Clinical validation is underway:
    • A first-in-human study at IHU Strasbourg led by Prof. Silvana Perretta.
    • A U.S. comparative trial at UCSF, led by Prof. Adnan Alseidi.

An Open Ecosystem for Surgical Innovation

Scialytics is actively seeking collaborations with:

  • Surgeons and hospitals aiming to raise safety and quality standards.
  • Investors looking for clinically validated healthtech with clear regulatory pathways.
  • Digital health innovators building complementary solutions in surgery.

For more information or partnership opportunities, visit scialytics.io.

Scialytics is yet another example of the ability of IHU Strasbourg — where clinicians, engineers and researchers work side by side — to transform pioneering research of excellence into a concrete solution that benefits patients and fosters business creation.

SRS 2025: the future of telesurgery takes shape between France and Germany

SRS 2025: the future of telesurgery takes shape between France and Germany

Robotic telesurgery: first cross-border demonstration between France and Germany with haptic feedback over 5G and Wi-Fi 6 networks

At the 2025 meeting of the Surgical Robotics Society (SRS), held in Strasbourg from July 16 to 20, Dr. Alain Garcia, surgeon and researcher at IHU Strasbourg, and Johannes Horsch, representing the Fraunhofer IPA Institute (Germany), presented a unique comparison between 5G and Wi-Fi 6 technologies for image-guided telesurgery procedures with haptic feedback.

The study, unveiled on July 18, focused on a procedure involving robot-assisted, image-guided percutaneous needle implantation on a mannequin. It was conducted between two hybrid operating rooms located 115 kilometers apart, one in Strasbourg and the other in Mannheim, connected by a secure VPN connection.

The system was based on:

  • A robotic arm equipped with a force detection motor to provide haptic feedback to the surgeon,
  • Remote planning and control via ROS2 and OpenIGTLink standards,
  • Local supervision at the patient site to ensure real-time safety.

The results are promising:

  • All procedures were successfully completed, both on a private 5G network and Wi-Fi 6,
  • Latency times remained within an acceptable range for remote surgery (approximately 42 ms on 5G and 50 ms on Wi-Fi 6).
  • Integration into the medical workflow proved seamless.

This collaboration is the first demonstration of telesurgery between France and Germany based on next-generation wireless networks, offering concrete prospects for a future where connectivity will expand access to specialized remote care.

Learn more about the project: www.ipa.fraunhofer.de

Pancreatic cancer: mAI Companion® to improve early diagnosis of pancreatic cancer

Pancreatic cancer: mAI Companion® to improve early diagnosis of pancreatic cancer

A new breakthrough in the early diagnosis of pancreatic cancer: mAI Companion®, AI for echoendoscopy.

At the Manchester Advanced Endoscopy Symposium – EUS/ERCP 2025, Dr. Leonardo Sosa Valencia, international expert and director of echoendoscopy courses at the IHU Strasbourg, presented an exclusive preview of mAI Companion®, a new AI-based tool to assist in the early diagnosis of pancreatic cancer.

Developed by the German company Medi-Globe Technologies GmbH, in close collaboration with the joint venture iGlobe Scientific founded with the IHU Strasbourg, mAI Companion® represents a real revolution for clinicians. Designed to be easy to use, fast, and reliable, this intelligent assistant analyzes echoendoscopy images in real time and assists physicians in the early detection of pancreatic lesions.

“Thanks to this innovation, we hope to take a major step forward in the fight against pancreatic cancer, where the quality of early diagnosis remains one of the main challenges,” says Dr. Sosa Valencia, who is also involved in several translational research projects combining AI, navigation, and advanced imaging.“

A strategic partnership against pancreatic cancer

mAI Companion® is a clinical decision support tool designed by and for echoendoscopy specialists. It aims to transform the screening and management of pancreatic diseases. It is the result of a research project initiated in 2021 by the IHU Strasbourg with the decisive support of the ARC Foundation for Cancer Research. The research prototype developed by IHU Strasbourg was transferred in 2023 to iGlobe Scientific, a joint venture created by IHU Strasbourg and Medi-Globe Technologies to develop a commercial product.

The rapid development of mAI Companion® was made possible by the close collaboration between medical expertise, cutting-edge research, and technological innovation. The upcoming commercialization of this medical device should strengthen the arsenal of gastroenterologists in Europe and beyond.

A driving force for the IHU Strasbourg

Since its creation, the IHU Strasbourg has placed care, research, innovation, and training at the heart of its mission. Through international programs such as the ITEC course, the center trains practitioners from around the world in the most advanced techniques of therapeutic echoendoscopy every year.

Today, the IHU reaffirms its commitment to advancing the medicine of tomorrow through ambitious partnerships and disruptive technological solutions that benefit patients.

To learn more about mAI Companion®:
Discover the tool on the Medi-Globe website

To learn more about iGlobe Scientific:
Read our article on the inauguration

To learn more about the ITEC course:
ITEC course page – IHU Strasbourg

2025 Awards – IHU Strasbourg wins for the FAST-Tx project: Fast Analysis and Surgical Treatment – Thorax

2025 Awards – IHU Strasbourg wins for the FAST-Tx project: Fast Analysis and Surgical Treatment – Thorax

On June 12, 2025, during the FORCE Foundation Awards Ceremony for Innovation and Research in Health, seven projects were recognized for their potential to transform the healthcare system. Among them, the FAST-Tx project, led by the Strasbourg University Hospital Institute, was hailed as a potential major breakthrough in the field of thoracic oncology.

An innovative patient pathway for personalized lung cancer treatment

FAST-Tx offers a paradigm shift in the care pathway for patients with suspicious lung nodules: diagnosis and intervention in less than 24 hours.

This integrated approach is based on a completely original technological and organizational ecosystem that will leverage synergies between world-class medical and surgical expertise, unparalleled clinical infrastructure, and innovations from companies.

The project illustrates the IHU Strasbourg’s strong commitment to developing image-guided, minimally invasive surgical pathways enhanced by robotics and artificial intelligence. The objective of FAST-Tx is clear: to accelerate patient care in order to increase the chances of recovery, improve the rates of complete resection of cancerous nodules, and offer a new standard of care that can be exported to other hospital facilities.

An exemplary collaborative dynamic

The project led by the IHU Strasbourg brings together key partners:

  • The thoracic surgery center and the diagnostic and therapeutic interventional bronchial endoscopy department of the Strasbourg University Hospitals,
  • Visible Patient Lab, the leading online laboratory for 3D modeling of medical images for the creation of digital twins,
  • ASARIA – Assisted Surgery by Augmented Reality & AI, which has developed an augmented reality device for pre- and intraoperative assistance in interventional procedures.

Led by Prof. Christian Debry (Director General of the IHU Strasbourg), with Prof. Pierre-Emmanuel Falcoz (thoracic surgery), Dr. Cezar Matau (bronchial endoscopy), Luc Soler (Visible Patient Lab), and Bernard Dubois (Asaria), the FAST-Tx team shares the same vision of a new generation of precise and personalized minimally invasive procedures. This synergy between clinical excellence, cutting-edge technologies, and hospital engineering demonstrates the ability of local stakeholders to innovate together for the benefit of patients.

A trophy that symbolizes a vision for the future

Awarded by the FORCE Foundation, which supports the emergence of innovative solutions to improve healthcare in the future, this trophy rewards boldness, scientific rigor, and collective commitment. The FAST-Tx project embodies a concrete response to the challenges of oncology, placing medical time, precision, and patient well-being at the heart of the system.

More info:

Article from Dernières Nouvelles d’Alsace (DNA), published on June 16, 2025:
The Force Foundation supports seven new research projects in Alsace

Fondation Force

The IHU Strasbourg is delighted with this recognition and will continue to work alongside its partners to advance medicine that is increasingly rapid, personalized, and efficient.

Pancreatic Cancer: Prof. Thomas Baumert wins prestigious ERC Proof of Concept Grant

Pancreatic Cancer: Prof. Thomas Baumert wins prestigious ERC Proof of Concept Grant

Pancreatic cancer is among the most dreaded: often with no early symptoms, it is diagnosed late and associated with an extremely poor prognosis. With the PACMAN project, supported by an ERC Proof of Concept Grant, Professor Thomas Baumert and his team are seeking to establish preclinical proof of concept for a new therapeutic approach.

An innovative therapy project

Pancreatic ductal adenocarcinoma (PDAC) is the most frequent and aggressive form of pancreatic cancer. With a median survival of less than a year, even with treatment, the need for new therapies is urgent. Thanks to €150,000 in funding from the European Research Council (ERC), the PACMAN project will test the efficacy of an innovative therapeutic candidate in patient-derived models, a key step in accelerating the transition to clinical trials.

This new project is part of the close collaboration between Inserm, the University of Strasbourg, the University Hospitals of Strasbourg and the IHU Strasbourg to transform scientific discoveries into concrete innovations for the benefit of patients.

European funding: synonymous with excellence

Created by the European Union in 2007, the ERC is a prestigious and highly selective European program for funding excellent research projects in various categories. This is the fifth time in eight years that Thomas Baumert has been awarded funding, this time in the “ERC Proof of Concept Grant” category, which aims to accelerate the transfer of research work to applications.

Read the press release dated January 24, 2025, published by the University of Strasbourg (in French)

 

Université de Strasbourg Inserm HUS